X
Xuyi Wang
Researcher at Hudson Institute of Medical Research
Publications - 10
Citations - 413
Xuyi Wang is an academic researcher from Hudson Institute of Medical Research. The author has contributed to research in topics: Aromatase & Medicine. The author has an hindex of 5, co-authored 5 publications receiving 298 citations. Previous affiliations of Xuyi Wang include Monash University, Clayton campus & Monash University.
Papers
More filters
Journal ArticleDOI
p53: protection against tumor growth beyond effects on cell cycle and apoptosis
TL;DR: The publication by Wang and colleagues demonstrates for the first time that p53 is a key negative regulator of aromatase and, hence, estrogen production in the breast tumor microenvironment and goes further by demonstrating that an important regulator of aromaase, the obesity-associated and tumor-derived factor prostaglandin E2, inhibits p53 in the Breast adipose stroma.
Journal ArticleDOI
Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer.
TL;DR: Evidence demonstrating a link between obesity and breast cancer has led to the investigation of metabolic pathways as novel regulators of estrogen production, including pathways that can be targeted to inhibit aromatase specifically within the breast.
Journal ArticleDOI
Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mechanism for the regulation of aromatase in obesity and breast cancer.
TL;DR: It is demonstrated that p53 is a negative regulator of aromatase in the breast and its inhibition by PGE2 provides a novel mechanism for aromat enzyme regulation in obesity and breast cancer.
Journal ArticleDOI
Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism
Maria Docanto,Fangyuan Yang,Brid Callaghan,Cherie Cheuk Man Au,Rahini Ragavan,Xuyi Wang,John B. Furness,Zane B. Andrews,Kristy A. Brown +8 more
TL;DR: The findings suggest that ghrelin acts at alternate receptors in ASCs by decreasing intracellular cAMP levels, and may be useful in the treatment of estrogen-dependent breast cancer.